A carregar...
A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer
LESSONS LEARNED. Single‐agent selinexor has limited activity in heavily pretreated patients with metastatic triple‐negative breast cancer. Selinexor 60 mg by mouth twice weekly was generally well tolerated with a side‐effect profile consistent with previous clinical trials. Future studies of selinex...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6656474/ https://ncbi.nlm.nih.gov/pubmed/30996012 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0231 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|